Treatment of CD19-Positive Mixed Phenotype Acute Leukemias With Blinatumomab

American Journal of Hematology - United States
doi 10.1002/ajh.25317
Full Text
Abstract

Available in full text

Categories
Hematology
Date
Authors
Publisher

Wiley

Related search

Efficiency of Blinatumomab in a T(8;21) Acute Myeloid Leukemia Expressing CD19

Haematologica
Hematology
2019English

Blinatumomab: A New Treatment for Adults With Relapsed Acute Lymphocytic Leukemia

Clinical Journal of Oncology Nursing
Oncology
2016English

Blinatumomab, a Bi-Specific Anti-Cd19/Cd3 BiTE® Antibody for the Treatment of Acute Lymphoblastic Leukemia: Perspectives and Current Pediatric Applications

Frontiers in Oncology
Cancer ResearchOncology
2014English

Outcome of Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia After Blinatumomab Failure: No Change in the Level of CD19 Expression

American Journal of Hematology
Hematology
2017English

Effects of Bosutinib Treatment on Renal Function in Patients With Philadelphia Chromosome-Positive Leukemias

Clinical Lymphoma, Myeloma and Leukemia
Cancer ResearchOncologyHematology
2017English

Blinatumomab in Acute Lymphoblastic Leukemia

Expert Review of Anticancer Therapy
OncologyPharmacology
2016English

BRAF Mutations in Acute Leukemias

Leukemia
Cancer ResearchOncologyAnesthesiologyPain MedicineHematology
2003English

Indirect Treatment Comparison of Inotuzumab Ozogamicin Versus Blinatumomab for Relapsed or Refractory Acute Lymphoblastic Leukemia

Advances in Therapy
MedicinePharmacology
2019English

Multiparameter Flow Cytometry Applications in the Diagnosis of Mixed Phenotype Acute Leukemia (MPAL)

Cytometry Part B - Clinical Cytometry
Forensic MedicinePathologyHistologyCell Biology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy